メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
プロジェクト
研究成果
データセット
受賞
活動
コース
専門知識、名前、または所属機関で検索
微生物学講座
富山大学
医学系
概要
フィンガープリント
ネットワーク
プロファイル
(4)
プロジェクト
(4)
研究成果
(257)
データセット
(1)
フィンガープリント
微生物学講座が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Methicillin-resistant Staphylococcus Aureus
64%
Influenza Virus
61%
COVID-19
61%
Pseudomonas Aeruginosa (P. aeruginosa)
58%
Pneumonia
52%
Japan
52%
Lung
43%
Streptococcus Pneumoniae
42%
Herpes Simplex Virus 2 (HSV-2)
42%
Azithromycin
40%
Murine Model
39%
Airway Epithelial Cells
38%
β-lactamase
35%
In Vivo Efficacy
34%
Quantitative PCR
34%
VacA
33%
Helicobacter Pylori (H. pylori)
33%
Mucin 5AC (MUC5AC)
33%
Mouse Model
33%
Gene Products
32%
Risk Factors
31%
Meropenem
30%
Vancomycin
29%
Haemophilus Influenzae
27%
Influenza-like Illness
27%
Infectious Diseases
25%
Nagasaki
25%
Protease
25%
Klebsiella Pneumoniae (K. pneumoniae)
23%
Metallo-β-lactamase
23%
Indonesia
22%
Chronic Pulmonary Aspergillosis
22%
Clarithromycin
22%
Macrolides
21%
S. Pneumoniae
21%
Infected Cells
21%
Hematogenous
21%
Antibacterial Susceptibility
21%
Clinical Characteristics
20%
Trypsin
20%
Antibiotics
20%
University Hospital
20%
Community-acquired Pneumonia
20%
Post-infection
20%
Clinical Microbiology
20%
Ventilator-associated Pneumonia
19%
Chemotherapy
19%
Pulmonary Infection
19%
Bacterial Respiratory Pathogens
18%
Japanese Society
18%
Nationwide Surveillance
18%
Minimum Inhibitory Concentration
18%
Molecular Diagnostics
18%
Airway
18%
Acute Respiratory Tract Infection
17%
Legionella Pneumophila
17%
Carbapenems
17%
Respiratory Infection
17%
Vacuolating Cytotoxin
16%
Neutralizing Antibodies
16%
Virus
16%
Herpes Simplex Virus Type 1 (HSV-1)
16%
Antimicrobial Susceptibility
15%
Viral Load
15%
Extended-spectrum-lactamase
14%
Virus Infection
14%
Clostridioides Difficile
14%
Fluoroquinolone Resistance
14%
Fluoroquinolones
14%
Ampicillin Resistance
14%
Patients with COVID-19
14%
Sendai Virus
14%
Infectivity
14%
Levofloxacin
13%
Human Influenza
13%
Clinical Features
13%
Cefepime
13%
Tertiary Hospital
13%
Sitafloxacin
13%
Resistant Strains
12%
Nucleic Acid Testing
12%
Healthcare-associated Pneumonia
12%
Enterobacteriaceae
12%
Adult T-cell Leukemia
12%
Overexpression
12%
Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV)
12%
Performance Evaluation
12%
Survival Rate
12%
Fusobacterium nucleatum (F. nucleatum)
12%
Quinolones
11%
CA-MRSA
11%
Bronchoalveolar Lavage Fluid
11%
Quinolone Resistance-determining Region
11%
DNA Synthesis
11%
Combination Therapy
11%
Bacteremia
11%
Immunomodulatory Effect
11%
Carbapenem Resistance
11%
Infection Model
10%
Older Men
10%
Immunology and Microbiology
Methicillin-Resistant Staphylococcus Aureus
63%
Influenza Virus
49%
Infectious Agent
46%
Pneumococcus
42%
Herpes Simplex Virus 2
42%
Influenzavirus A
41%
Minimum Inhibitory Concentration
36%
Viral Disease
34%
Helicobacter Pylori
33%
Gene Product
33%
COVID-19
32%
Severe Acute Respiratory Syndrome Coronavirus 2
30%
Glycoprotein
28%
Influenza
27%
Pseudomonas aeruginosa
25%
MUC5AC
25%
DNA Virus
24%
Staphylococcus Aureus
23%
Immunology
22%
Neutralizing Antibody
22%
Infectious Disease
22%
Haemophilus influenzae
21%
Streptococcus Pneumonia
21%
DNA Synthesis
20%
Mouse Model
19%
Clinical Microbiology
18%
Antibiotic Sensitivity
18%
Mitochondrion
16%
Klebsiella pneumoniae
16%
Viral Load
16%
Immunofluorescence
16%
Wild Type
15%
Penicillin
15%
Plasmid
15%
Enterobacteriaceae
14%
Survival Rate
14%
Human Alphaherpesvirus 1
14%
Escherichia coli
14%
Bronchoalveolar Lavage Fluid
14%
Viral Replication
14%
Abscess
13%
Legionella pneumophila
12%
Epstein Barr Virus
12%
Virion
12%
Amino Terminal Sequence
12%
Cytokine
12%
Upper Respiratory Tract
12%
Viral Entry
11%
Capsid
11%
Colony Forming Unit S
11%
Virogenesis
11%
Pharmacokinetics
11%
Antiserum
11%
interferon
11%
Pathogenicity
11%
Antibody Response
11%
Sendai Virus
10%
Omicron Coronavirus Variant
10%
Aspergillus
10%
Matrix-Assisted Laser Desorption-Ionization
10%
Cell Death
10%
Neutralization
10%
Precursor
10%
Human T-Lymphotropic Virus 1
10%
Viral Envelope
9%
Virus Infectivity
9%
DNA Polymerase
9%
Fusobacterium nucleatum
9%
Mitochondrial Membrane Potential
9%
Antimicrobial Resistance
9%
Hemagglutinin
8%
Gene Expression
8%
Aspergillus fumigatus
8%
Genetic Transfection
8%
T Cell
8%
Multiplex Polymerase Chain Reaction
8%
Real Time Polymerase Chain Reaction
8%
Pyrosequencing
8%
Cytomegalovirus
8%
Acinetobacter Baumannii
8%
Prevotella intermedia
8%
Aeromonas
8%
Fusobacterium necrophorum
8%
Western Blot
8%
Drug Megadose
8%
Polyclonal Antiserum
8%
Leporidae
8%
Cell Lysate
8%
Sputum
8%
Blood Plasma
8%
Morphology
7%
Supernatant
7%
Polymerase Chain Reaction
7%
Interleukin 6
7%
Mucin
7%
Microflora
7%
Pulmonary Inflammation
7%
Quantitative Reverse Transcription Polymerase Chain Reaction
7%
Molecular Weight
6%
Herpes Simplex Virus
6%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
100%
Methicillin-Resistant Staphylococcus Aureus
55%
Pseudomonas aeruginosa
54%
Penicillinase
42%
SARS Coronavirus
39%
Azithromycin
32%
Mucin 5AC
31%
Macrolide
29%
Respiratory Tract Infection
28%
Infectious Agent
26%
Antiinfective Agent
25%
Disease
25%
Helicobacter Pylori
25%
Quinolone Derivative
24%
Mouse Model
24%
Proteinase
23%
Vancomycin
23%
Virus Infection
20%
Streptococcus
20%
Pharmacokinetics
20%
Methicillin Resistant Staphylococcus Aureus Infection
20%
Vacuolating Toxin
18%
Clarithromycin
18%
Influenza Virus
17%
Haemophilus influenzae
17%
Meropenem
17%
Ventilator Associated Pneumonia
15%
Lung Infection
14%
Antibiotics
14%
Influenzavirus A
14%
Lung Aspergillosis
14%
Coronavirinae
14%
Bloodstream Infection
14%
Legionella pneumophila
13%
Sitafloxacin
13%
Mucin
12%
Severe Fever with Thrombocytopenia Syndrome
12%
Community Acquired Pneumonia
12%
Levofloxacin
11%
Neutralizing Antibody
11%
Messenger RNA
11%
Quinolone
11%
Staphylococcus Aureus
10%
Ampicillin
10%
Amphotericin B
10%
Carbapenem Resistance
10%
Cytokine
10%
Linezolid
10%
Garenoxacin
10%
Aspergillus
10%
Tumor Necrosis Factor
9%
Respiratory Failure
9%
Penicillin Derivative
9%
Glycoprotein
9%
Fusobacterium nucleatum
9%
Virus Infectivity
9%
Health Care Associated Pneumonia
9%
Biapenem
9%
Streptococcus Pneumonia
9%
Aspergillus fumigatus
9%
Chemotherapy
8%
Carbapenem
8%
Minimum Inhibitory Concentration
8%
Amino Acid
8%
Pazufloxacin
8%
Nontypeable Haemophilus Influenzae
8%
Habekacin
8%
Tedizolid
8%
T Cell Leukemia
8%
Inosine Phosphate
8%
Peptoclostridium difficile
8%
Tobramycin
8%
Herpes Simplex Virus 2
8%
Clinical Feature
8%
Interferon Type I
8%
Prevotella intermedia
8%
Acinetobacter Baumannii
8%
Antibiotic Resistance
8%
Aeromonas
8%
Itraconazole
8%
Carbapenem Derivative
8%
Pulmonary Surfactant
7%
Ciprofloxacin
7%
Aminoglycoside
7%
Fatality
7%
Interleukin 6
7%
Favipiravir
7%
Combination Therapy
7%
Survival Rate
7%
Adenosine Triphosphate
7%
Inflammation
6%
Klebsiella pneumoniae
6%
Panton-Valentine Leukocidin
6%
Antibiotic Therapy
6%
Metronidazole
6%
Moxifloxacin
6%
Randomized Controlled Trial
6%
Cytochrome C
6%
Triazole
6%
Molecular Epidemiology
6%